Literature DB >> 22096242

Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure.

Michael R DeBaun1, Sharada A Sarnaik, Mark J Rodeghier, Caterina P Minniti, Thomas H Howard, Rathi V Iyer, Baba Inusa, Paul T Telfer, Melanie Kirby-Allen, Charles T Quinn, Françoise Bernaudin, Gladstone Airewele, Gerald M Woods, Julie Ann Panepinto, Beng Fuh, Janet K Kwiatkowski, Allison A King, Melissa M Rhodes, Alexis A Thompson, Mark E Heiny, Rupa C Redding-Lallinger, Fenella J Kirkham, Hernan Sabio, Corina E Gonzalez, Suzanne L Saccente, Karen A Kalinyak, John J Strouse, Jason M Fixler, Mae O Gordon, J Phillip Miller, Michael J Noetzel, Rebecca N Ichord, James F Casella.   

Abstract

The most common form of neurologic injury in sickle cell anemia (SCA) is silent cerebral infarction (SCI). In the Silent Cerebral Infarct Multi-Center Clinical Trial, we sought to identify risk factors associated with SCI. In this cross-sectional study, we evaluated the clinical history and baseline laboratory values and performed magnetic resonance imaging of the brain in participants with SCA (HbSS or HbSβ° thalassemia) between the ages of 5 and 15 years with no history of overt stroke or seizures. Neuroradiology and neurology committees adjudicated the presence of SCI. SCIs were diagnosed in 30.8% (251 of 814) participants who completed all evaluations and had valid data on all prespecified demographic and clinical covariates. The mean age of the participants was 9.1 years, with 413 males (50.7%). In a multivariable logistic regression analysis, lower baseline hemoglobin concentration (P < .001), higher baseline systolic blood pressure (P = .018), and male sex (P = .030) were statistically significantly associated with an increased risk of an SCI. Hemoglobin concentration and systolic blood pressure are risk factors for SCI in children with SCA and may be therapeutic targets for decreasing the risk of SCI. This study is registered at www.clinicaltrials.gov as #NCT00072761.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22096242      PMCID: PMC3335377          DOI: 10.1182/blood-2011-05-349621

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  33 in total

1.  Multicenter prospective study of children with sickle cell disease: radiographic and psychometric correlation.

Authors:  F Bernaudin; S Verlhac; F Fréard; F Roudot-Thoraval; M Benkerrou; I Thuret; R Mardini; J P Vannier; E Ploix; M Romero; C Cassé-Perrot; M Helly; E Gillard; G Sebag; H Kchouk; J P Pracros; B Finck; J N Dacher; V Ickowicz; C Raybaud; M Poncet; E Lesprit; P H Reinert; P Brugières
Journal:  J Child Neurol       Date:  2000-05       Impact factor: 1.987

2.  Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease.

Authors:  S T Miller; E A Macklin; C H Pegelow; T R Kinney; L A Sleeper; J A Bello; L D DeWitt; D M Gallagher; L Guarini; F G Moser; K Ohene-Frempong; N Sanchez; E P Vichinsky; W C Wang; D L Wethers; D P Younkin; R A Zimmerman; M R DeBaun
Journal:  J Pediatr       Date:  2001-09       Impact factor: 4.406

3.  Cerebrovascular complications and parvovirus infection in homozygous sickle cell disease.

Authors:  K J Wierenga; B E Serjeant; G R Serjeant
Journal:  J Pediatr       Date:  2001-09       Impact factor: 4.406

4.  Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke.

Authors:  Douglas J Scothorn; Cynthia Price; Daniel Schwartz; Cindy Terrill; George R Buchanan; Wanda Shurney; Ingrid Sarniak; Robert Fallon; Jen-Yih Chu; Charles H Pegelow; Winfred Wang; James F Casella; Linda S Resar; Brian Berman; Thomas Adamkiewicz; Lewis L Hsu; Kwaku Ohene-Frempong; Kim Smith-Whitley; Donald Mahoney; J Paul Scott; Gerald M Woods; Masayo Watanabe; Michael R Debaun
Journal:  J Pediatr       Date:  2002-03       Impact factor: 4.406

5.  Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease.

Authors:  Charles H Pegelow; Eric A Macklin; Franklin G Moser; Winfred C Wang; Jacqueline A Bello; Scott T Miller; Elliott P Vichinsky; Michael R DeBaun; Ludovico Guarini; Robert A Zimmerman; Donald P Younkin; Dianne M Gallagher; Thomas R Kinney
Journal:  Blood       Date:  2002-04-15       Impact factor: 22.113

6.  Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study.

Authors:  Sarah E Vermeer; Peter J Koudstaal; Matthijs Oudkerk; Albert Hofman; Monique M B Breteler
Journal:  Stroke       Date:  2002-01       Impact factor: 7.914

7.  Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort.

Authors:  Françoise Bernaudin; Suzanne Verlhac; Cécile Arnaud; Annie Kamdem; Sylvie Chevret; Isabelle Hau; Lena Coïc; Emmanuella Leveillé; Elisabeth Lemarchand; Emmanuelle Lesprit; Isabelle Abadie; Nadia Medejel; Fouad Madhi; Sophie Lemerle; Sandra Biscardi; Josiane Bardakdjian; Frédéric Galactéros; Martine Torres; Mathieu Kuentz; Christelle Ferry; Gérard Socié; Philippe Reinert; Christophe Delacourt
Journal:  Blood       Date:  2010-11-10       Impact factor: 22.113

8.  Central nervous system abnormalities in asymptomatic young patients with Sbeta-thalassemia.

Authors:  Dimitrios I Zafeiriou; Mara Prengler; Nikos Gombakis; Konsantinos Kouskouras; Marina Economou; Achileas Kardoulas; Chaido Tsantali; Athanasios Dimitriadis; Miranta Athanasiou; Fenella J Kirkham
Journal:  Ann Neurol       Date:  2004-06       Impact factor: 10.422

9.  Reversible posterior leukoencephalopathy syndrome and silent cerebral infarcts are associated with severe acute chest syndrome in children with sickle cell disease.

Authors:  Jessica N Henderson; Michael J Noetzel; Robert C McKinstry; Desiree A White; Melissa Armstrong; Michael R DeBaun
Journal:  Blood       Date:  2002-09-26       Impact factor: 22.113

10.  Asymptomatic cerebral lacunae in patients with chronic kidney disease.

Authors:  Shuzo Kobayashi; Toshio Ikeda; Hidekazu Moriya; Takayasu Ohtake; Hiromichi Kumagai
Journal:  Am J Kidney Dis       Date:  2004-07       Impact factor: 8.860

View more
  68 in total

Review 1.  Vasculopathy of Aging and the Revised Cardiovascular Continuum.

Authors:  Su-A Kim; Jeong Bae Park; Michael F O'Rourke
Journal:  Pulse (Basel)       Date:  2015-08-20

2.  Cognitive functioning in children from Nigeria with sickle cell anemia.

Authors:  Olubusola B Oluwole; Robert B Noll; Daniel G Winger; Olu Akinyanju; Enrico M Novelli
Journal:  Pediatr Blood Cancer       Date:  2016-07-09       Impact factor: 3.167

3.  CE: Understanding the Complications of Sickle Cell Disease.

Authors:  Paula Tanabe; Regena Spratling; Dana Smith; Peyton Grissom; Mary Hulihan
Journal:  Am J Nurs       Date:  2019-06       Impact factor: 2.220

Review 4.  Subclinical Cerebrovascular Disease: Epidemiology and Treatment.

Authors:  Adam de Havenon; Chelsea Meyer; J Scott McNally; Matthew Alexander; Lee Chung
Journal:  Curr Atheroscler Rep       Date:  2019-07-27       Impact factor: 5.113

Review 5.  Measuring success: utility of biomarkers in sickle cell disease clinical trials and care.

Authors:  Ram Kalpatthi; Enrico M Novelli
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 6.  Interventions for preventing silent cerebral infarcts in people with sickle cell disease.

Authors:  Lise J Estcourt; Patricia M Fortin; Sally Hopewell; Marialena Trivella; Carolyn Doree; Miguel R Abboud
Journal:  Cochrane Database Syst Rev       Date:  2017-05-13

Review 7.  Proteomic and biomarker studies and neurological complications of pediatric sickle cell disease.

Authors:  Eboni I Lance; James F Casella; Allen D Everett; Emily Barron-Casella
Journal:  Proteomics Clin Appl       Date:  2014-11-06       Impact factor: 3.494

8.  Headache and migraine in children with sickle cell disease are associated with lower hemoglobin and higher pain event rates but not silent cerebral infarction.

Authors:  Michael M Dowling; Michael J Noetzel; Mark J Rodeghier; Charles T Quinn; Deborah G Hirtz; Rebecca N Ichord; Janet L Kwiatkowski; E Steven Roach; Fenella J Kirkham; James F Casella; Michael R DeBaun
Journal:  J Pediatr       Date:  2014-02-13       Impact factor: 4.406

9.  Biological impact of α genes, β haplotypes, and G6PD activity in sickle cell anemia at baseline and with hydroxyurea.

Authors:  Françoise Bernaudin; Cécile Arnaud; Annie Kamdem; Isabelle Hau; Françoise Lelong; Ralph Epaud; Corinne Pondarré; Serge Pissard
Journal:  Blood Adv       Date:  2018-03-27

10.  Thrombospondin-1 and L-selectin are associated with silent cerebral infarct in children with sickle cell anaemia.

Authors:  Lisa M Faulcon; Zongming Fu; Pratima Dulloor; Emily Barron-Casella; William Savage; Jacky M Jennings; Jennifer E Van Eyk; Michael Debaun; James F Casella; Allen Everett
Journal:  Br J Haematol       Date:  2013-05-14       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.